| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 18.06% | Needham | $9 → $4.25 | Maintains | Buy |
| 04/04/2023 | -87.5% | Needham | $1.4 → $0.45 | Maintains | Buy |
| 12/01/2022 | -86.11% | Lake Street | $3 → $0.5 | Downgrades | Buy → Hold |
| 11/18/2022 | -86.11% | Piper Sandler | $1 → $0.5 | Downgrades | Overweight → Neutral |
| 11/14/2022 | -72.22% | Piper Sandler | $1.5 → $1 | Maintains | Overweight |
| 11/11/2022 | -61.11% | Needham | $2.1 → $1.4 | Maintains | Buy |
| 08/17/2022 | -58.33% | Piper Sandler | $1.4 → $1.5 | Maintains | Overweight |
| 08/11/2022 | -16.67% | Lake Street | $6 → $3 | Maintains | Buy |
| 08/11/2022 | -41.67% | Needham | $2.25 → $2.1 | Maintains | Buy |
| 05/24/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 05/16/2022 | -61.11% | Piper Sandler | $1.8 → $1.4 | Maintains | Overweight |
| 05/12/2022 | -37.5% | Needham | $4 → $2.25 | Maintains | Buy |
| 03/18/2022 | -50% | Piper Sandler | $3.1 → $1.8 | Maintains | Overweight |
| 03/14/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 03/11/2022 | 66.67% | Lake Street | $11 → $6 | Maintains | Buy |
| 03/11/2022 | 11.11% | Needham | $5 → $4 | Maintains | Buy |
| 01/07/2022 | -13.89% | Stephens & Co. | → $3.1 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 38.89% | Needham | $7 → $5 | Maintains | Buy |
| 11/10/2021 | 94.44% | Needham | $8 → $7 | Maintains | Buy |
| 03/17/2021 | 122.22% | Needham | → $8 | Assumes | → Buy |
| 12/16/2020 | 11.11% | Piper Sandler | $2 → $4 | Upgrades | Neutral → Overweight |
| 11/30/2020 | 38.89% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 11/13/2020 | 11.11% | Needham | $2 → $4 | Maintains | Buy |
| 11/10/2020 | 38.89% | Keybanc | → $5 | Initiates Coverage On | → Overweight |
| 07/30/2020 | 66.67% | Benchmark | $7 → $6 | Maintains | Speculative Buy |
| 07/01/2020 | -44.44% | Needham | $4 → $2 | Maintains | Buy |
| 06/30/2020 | -44.44% | Chardan Capital | $7.75 → $2 | Downgrades | Buy → Neutral |
| 06/02/2020 | 11.11% | Needham | → $4 | Initiates Coverage On | → Buy |
| 02/13/2019 | 66.67% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
What is the target price for OncoCyte (OCX)?
The latest price target for OncoCyte (NASDAQ: OCX) was reported by Needham on August 10, 2023. The analyst firm set a price target for $4.25 expecting OCX to rise to within 12 months (a possible 18.06% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OncoCyte (OCX)?
The latest analyst rating for OncoCyte (NASDAQ: OCX) was provided by Needham, and OncoCyte maintained their buy rating.
When is the next analyst rating going to be posted or updated for OncoCyte (OCX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OncoCyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OncoCyte was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating OncoCyte (OCX) correct?
While ratings are subjective and will change, the latest OncoCyte (OCX) rating was a maintained with a price target of $9.00 to $4.25. The current price OncoCyte (OCX) is trading at is $3.60, which is out of the analyst's predicted range.